Remember......
-Dimerix is on track to release final data for its Phase 2 Part A study in Chronic Kidney Disease in July 2017
- Interim study data released in November 2016 was positive and well received by clinicians in the sector
- The data released to date compares favourably with other larger pharmaceutical and drug research companies active in the same market sector
- The company will initiate a Phase 2 Part B study in the second half of 2017
- Dimerix believes if the Phase 2 Part A data scheduled for release in July 2017 is positive, it will be supportive of a potential licensing or partnering.
(asx april 11 2017)
Compelling stuff. Id like to think a few large companies are keenly awaiting results.
DXB Share Price, page-209
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
37.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $209.1M | |||
| Open | High | Low | Value | Volume |
| 38.0¢ | 38.5¢ | 36.5¢ | $579.4K | 1.548M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 91570 | 37.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 37.5¢ | 7922 | 2 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| DXB (ASX) Chart |